T-DXd Established as Standard of Care Following ET in HER2-Low, -Ultralow HR+ Metastatic Breast Cancer
Data from the phase 3 DESTINY-Breast06 trial (NCT04494425) demonstrated that fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu; AstraZeneca and Daiichi Sankyo) showed statistically significant and clinically meaningful improvement in progression-free …